title: Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia.
abstract: The selection of antimicrobial agents in the 2006 Guidelines (consensus statement) on Empiric Therapy for Complicated Intra-Abdominal Infections (IAIs) in Asia was based on resistance and epidemiological data from the Asian region. In these 2006 guidelines, single agent therapy using the beta-lactam/beta-lactamase inhibitors ampicillin/sulbactam or cefoperazone-sulbactam is recommended for mild-to-moderate cases, while piperacillin-tazobactam is recommended for high-severity cases. When using carbapenems, ertapenem is recommended for mild-to-moderate cases, while imipenem and meropenem are recommended for high-severity cases. For combination regimes, two types of agents are recommended: cephalosporin-based and monobactam-based. For mild-to-moderate cases, a third generation cephalosporin plus metronidazole is recommended. For high-severity cases, a third or fourth generation cephalosporin plus metronidazole+/-amikacin is recommended. For the monobactam-based regimen, aztreonam plus metronidazole is recommended for high-severity cases only.
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei, Taiwan. hsporen@ha.mc.ntu.edu.tw
authors.forename: Po-Ren
authors.initials: PR
authors.lastname: Hsueh
authors.forename: Peter Michael
authors.initials: PM
authors.lastname: Hawkey
mesh_terms: D000005:Abdomen; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D001208:Asia / Q000453:epidemiology; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D032921:Consensus; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000472:pathogenicity; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010878:Piperacillin / Q000494:pharmacology / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D017410:Practice Guidelines as Topic; D065093:beta-Lactamase Inhibitors
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D065093:beta-Lactamase Inhibitors; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin